• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kymera Therapeutics upgraded by BofA Securities with a new price target

    6/2/25 1:59:29 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    BofA Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $51.00
    Get the next $KYMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    6/3/2025$79.00Equal-Weight → Overweight
    Morgan Stanley
    6/3/2025$60.00Neutral → Buy
    B. Riley Securities
    6/2/2025$51.00Neutral → Buy
    BofA Securities
    5/20/2025$55.00Buy
    Stifel
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    12/2/2024$57.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kymera Therapeutics Announces Pricing of $250 Million Public Offering

      WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr

      6/26/25 11:56:15 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Proposed Public Offering

      WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares

      6/25/25 4:05:00 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

      Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partn

      6/25/25 7:05:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care